Diagnosis and differential assessment of pulmonary arterial hypertension.

By R. Barst, M. McGoon, A. Torbicki, O. Sitbon, M. Krowka, H. Olschewski, S. Gaine. Journal of the American College of Cardiology, 2004

1,037 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/fa5017fecf4f885336c29f86caae747c37e45a29

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. G. Simonneau

Citations in the corpus

• Tadalafil Therapy for Pulmonary Arterial Hypertension (2009, neutral): “Male 17 (21) 18 (22) 13 (16) 20 (24) 20 (25)”
• The changing epidemiology of congenital heart disease (2011, background): “Pulmonary arterial hypertension (PAH) is caused by intra-cardiac left-to-right shunting and pulmonary blood volume overload”
• Pulmonary arterial hypertension (2013, background): “Barst and colleagues [183] showed improvement in exercise capacity with an increase in 6-MWD of 47meters after 12 months of epoprostenol treatment in 81 patients with idiopathic PAH.”
• Pulmonary arterial hypertension in France: results from a national registry. (2006, background): “Irrespective of the PAH subtype, a majority of the patients were diagnosed in NYHA functional class III or IV, even in the setting of diseases such as systemic sclerosis, congenital heart diseases, or portal hypertension, where screening for PAH using Doppler echocardiography may be performed (9).”